Blackstone Signs Definitive Agreement to Acquire Takeda Consumer Healthcare Company; Financial Terms Not Disclosed
Blackstone (NYSE: BX) announced today that funds managed by The Blackstone Group Inc.
Benzinga · 08/24/2020 09:25
Blackstone (NYSE: BX) announced today that funds managed by The Blackstone Group Inc. and its affiliates (collectively, "Blackstone") have entered into a definitive agreement to acquire Takeda Consumer Healthcare Company Limited ("TCHC"), a subsidiary of Takeda Pharmaceutical Company Limited (NYSE: TAK) and a leading provider of over-the-counter medicines in Japan. For more than 66 years, TCHC's flagship vitamin drug Alinamin has been a staple product in Japanese households. In addition to Alinamin vitamin tablets and drinks, TCHC offers a platform of other over-the-counter products, including Benza Block, a leading symptom based cold remedy. Atsuhiko Sakamoto, Head of Private Equity in Blackstone Japan, commented: "We are privileged to announce this partnership and invest in the company's plans to become the leading consumer healthcare business in Japan. TCHC is well-positioned to grow its established brands in Japan and launch new and expanded product offerings. We see tremendous potential for TCHC in Japan and throughout Asia, and we are confident that Blackstone's global network and expertise in the sector can accelerate TCHC's growth." Milano Furuta, Chairman of the Board, Takeda Consumer Healthcare Company, said: "Throughout decades, TCHC's brands including Alinamin have earned the trust and confidence of consumers in Japan. We believe the active and strategic investment by Blackstone will enable TCHC to maximize its potential. Blackstone is one of the world's leading investment firms and has rich experience in the healthcare sector, and we are confident this will help TCHC further develop its products and brands and strengthen the business overall." The transaction marks Blackstone's second private equity transaction in Japan's healthcare sector following the acquisition of AYUMI Pharmaceutical in 2019. Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. is acting as exclusive financial advisor to Blackstone, while Simpson Thacher & Bartlett LLP and Anderson Mori & Tomotsune are acting as legal advisors.